An observational study in ARDS, Human and COVID-19 Acute Respiratory Distress Syndrome, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
The primary endpoint of this research is to establish that the alveolar dead space is significantly higher in patients with COVID-19 ARDS, compared to patients with non-COVID-19 ARDS.
Secondarily, the investigators want to establish the prognostic value of the alveolar-dead space (measured iteratively) in patients with COVID-19 and non-COVID-19 ARDS, to establish the respective influences of the biological parameters of endothelial damage, of the biological parameters of coagulopathy, of the parameters set on the artificial ventilator on the value of the alveolar dead space; in ARDS patients with COVID-19 and non-COVID-19 ARDS, to establish the prognostic value of the laboratory parameters of endothelial damage and coagulopathy in patients with COVID-19 and non-COVID-19 ARDS.
Endothelial damage and coagulation activation at the lung microvascular level may play an important role in the physiopathology of the COVID-19 ARDS. The project aims to prospectively investigate both bedside pulmonary physiological markers and biological markers of coagulopathy and endothelial dysfunction in COVID-19 and non-COVID-19 ARDS patients.
1,597 studies on the registry are indexed under Respiratory Distress Syndrome; 312 are open to participants now.
This study's enrollment of 39 is below the median of 100 across 540 observational studies indexed under Respiratory Distress Syndrome.
Browse Respiratory Distress Syndrome studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with moderate or severe ARDS linked or not with covid-19
Exclusion Criteria:
20 patients with acute respiratory distress syndrome (ARDS) unrelated to COVID-19
Diagnostic Test: alveolar dead-space quantification · Diagnostic Test: Coagulation activation and impaired fibrinolysis explorations · Diagnostic Test: Endothelial activation / endothelial senescence
20 patients with acute respiratory distress syndrome (ARDS) linked to COVID-19
Diagnostic Test: alveolar dead-space quantification · Diagnostic Test: Coagulation activation and impaired fibrinolysis explorations · Diagnostic Test: Endothelial activation / endothelial senescence
measurement of alveolar dead-space based on volumetric capnography
blood sampling: * Fibrinolytic components * NETs components * Elastase-derived fragments of proteins of interest
circulating endothelial cells, E-selectin, endoglin, LVEF-A, LVEFR-2, Angiopoietin -1 and -2, cKit and SDF-1 Willebrand factor (activity, antigen, multimeric analysis )
Prognostic value of alveolar dead space
Recording the exhaled CO2 curve (side-stream capnography method) and volume curve, as determined by the mechanical ventilator, and computing the signals with the arterial CO2 partial pressure, reflecting the partial pressure of CO2 in the alveoli participating in gas exchanges), determined on arterial blood gas (ABG) sampling.
Time frame: Up to 28 days
Prognostic value of the alveolar dead space (measured iteratively)
To establish the link between alveolar dead-space values and Day 20 mortality
Time frame: 20 days
Prognostic value of the alveolar dead space (measured iteratively)
To establish the link between alveolar dead-space values and Day 20 mortality and Day-28 invasive ventilator-free days.
Time frame: 28 days
Level of circulating endothelial cells
To describe the biological parameters of endothelial damage and prognostic value
Time frame: Up to 28 days
Level of progenitor cells
To describe the biological parameters of endothelial damage and prognostic value
Time frame: Up to 28 days
Level of circulating stem cells
To describe the biological parameters of endothelial damage and prognostic value
Time frame: Up to 28 days
Level of endothelial proteomics
To describe the biological parameters of endothelial damage and prognostic value
Time frame: Up to 28 days
Level of D-dimers
To describe the biological parameters of endothelial damage and prognostic value
Time frame: Up to 28 days
Level of Willebrand Factor
To describe the biological parameters of endothelial damage and prognostic value
Time frame: Up to 28 days
Level of components of the fibrinolytic system
To describe the biological parameters of endothelial damage and prognostic value
Time frame: Up to 28 days
Level of fragments of plasminogen
To describe the biological parameters of endothelial damage and prognostic value
Time frame: Up to 28 days
Level of the components of the NETs (Neutrophil Extracellular Traps)
To describe the biological parameters of endothelial damage and prognostic value
Time frame: Up to 28 days
Survival rate
Time frame: 90 days
Plan to share: Yes — Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared
Supporting information: Study protocol, Icf
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome→
Assistance Publique - Hôpitaux de Paris